Sector
PharmaceuticalsOpen
₹5,151.05Prev. Close
₹5,154.9Turnover(Lac.)
₹347.97Day's High
₹5,265Day's Low
₹5,05552 Week's High
₹5,85052 Week's Low
₹4,636.55Book Value
₹428.61Face Value
₹10Mkt Cap (₹ Cr.)
8,714.68P/E
34.84EPS
147.87Divi. Yield
5.05Y/e 31 Mar( In .Cr) | Jun-2024 | Jun-2023 | Jun-2022 | Jun-2021 |
---|---|---|---|---|
Equity Capital | 16.6 | 16.6 | 16.6 | 16.6 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 521.64 | 734.29 | 599.89 | 687.11 |
Net Worth | 538.24 | 750.89 | 616.49 | 703.71 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Jun-2021 | Jun-2020 | Dec-2017 | Dec-2016 |
---|---|---|---|---|
Revenue | 1,008.73 | 1,355.86 | 1,103.96 | 992.56 |
yoy growth (%) | -25.6 | 22.81 | 11.22 | 5.64 |
Raw materials | -314.82 | -431.44 | -441.09 | -411.54 |
As % of sales | 31.2 | 31.82 | 39.95 | 41.46 |
Employee costs | -150.47 | -182.93 | -169.64 | -154.23 |
Y/e 31 Mar( In .Cr) | Jun-2021 | Jun-2020 | Dec-2017 | Dec-2016 |
---|---|---|---|---|
Profit before tax | 233.28 | 354.85 | 135.19 | 115.17 |
Depreciation | -30.04 | -29.45 | -26.4 | -24.81 |
Tax paid | -56.48 | -100.77 | -58.28 | -36.04 |
Working capital | -233.3 | 269.12 | 35.2 | 57.07 |
Other operating items |
Y/e 31 Mar | Jun-2021 | Jun-2020 | Dec-2017 | Dec-2016 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -25.6 | 22.81 | 11.22 | 5.64 |
Op profit growth | -21.99 | 129.18 | 19.07 | 38.5 |
EBIT growth | -34.03 | 162.48 | 17.38 | 38.2 |
Net profit growth | -30.41 | 170.55 | 18.67 | 47.74 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,698.35 | 129.24 | 4,07,155.15 | 1,181.05 | 0.8 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,549.7 | 71.05 | 1,47,295.24 | 594 | 0.54 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,444.25 | 25.07 | 1,16,664.33 | 1,438.15 | 0.9 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,183.9 | 59.03 | 1,07,673.27 | 485 | 0.88 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,458.1 | 52.42 | 1,01,358.17 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Independent Directo
S N Talwar
Independent Director
Rani A Jadhav
Managing Director
Milind Thatte
Non Executive Director
Aalok Agrawal
Company Sec. & Compli. Officer
Zeal Shah
Independent Director
S Madhavan
Executive Director
Lokesh Chandak
Non Executive Director
Seema Sambasivan
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Procter & Gamble Health Ltd
Summary
Procter & Gamble Health Limited was erstwhile incorporated as E Merck (India) Limited in year 1967. The Companys name was changed from E Merck (India) Limited to Merck Limited on March 27, 2002. Later, the name of the Company was changed to Procter & Gamble Health Limited on 6 May, 2019. The company was set up to take over the business of the Indian branch of Emeda Exports with all their assets and liabilities. The company is a 51% subsidiary of German firm Merck KGaA, is a leading player in vitamin formulations.Procter & Gamble Health Limited is an Indian-based company principally engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals. The company is the supplier of Pharmaceutical Chemicals, Formulated Chemical Products, Chemicals, Industrial Chemicals, Chemicals, Pharmaceutical Industry, and Chemical Products. The company offers prescription drugs, biotechnology products, and consumer health products, including over-the-counter products. They also offer products for the treatment of cancer, neurodegenerative diseases, infertility, endocrine and metabolic disorders, cardiovascular diseases, and other conditions with unmet medical needs.The company operates in two business divisions, namely Pharmaceuticals and Chemicals. The Pharmaceuticals business comprises of Ethicals used in the treatment of Cardiovascular and Metabolic diseases & Vitamin-based formulations and Consumer Health Care Products. The Chemicals business comprises of Bulk Drugs
Read More
The Procter & Gamble Health Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹5250 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Procter & Gamble Health Ltd is ₹8714.68 Cr. as of 02 Apr ‘25
The PE and PB ratios of Procter & Gamble Health Ltd is 34.84 and 14.01 as of 02 Apr ‘25
The 52-week high/low is the highest and lowest price at which a Procter & Gamble Health Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Procter & Gamble Health Ltd is ₹4636.55 and ₹5850 as of 02 Apr ‘25
Procter & Gamble Health Ltd's CAGR for 5 Years at 7.07%, 3 Years at 7.35%, 1 Year at 7.81%, 6 Month at -6.90%, 3 Month at -1.24% and 1 Month at -0.10%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.